PARP1 and neoplasm: PARP inhibitors (PARPis), which repress the catalytic activity of PARP, lead to tumor-specific cell death due to the combined deficiency in the HR and SSB repair pathway evoked by BRCA1/2 mutations and PARP inhibition respectively (145).